Zenith Drugs Ltd
Incorporated in 2000, Zenith Drugs Ltd is in the business of manufacturing
and trading of medicines[1]
- Market Cap ₹ 119 Cr.
- Current Price ₹ 69.5
- High / Low ₹ 154 / 47.2
- Stock P/E 11.3
- Book Value ₹ 36.3
- Dividend Yield 0.72 %
- ROCE 27.1 %
- ROE 26.3 %
- Face Value ₹ 10.0
Pros
Cons
- Company has high debtors of 188 days.
- Working capital days have increased from 102 days to 157 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 92 | 114 | 131 | |
| 85 | 104 | 114 | |
| Operating Profit | 7 | 9 | 17 |
| OPM % | 8% | 8% | 13% |
| 1 | 1 | 1 | |
| Interest | 2 | 2 | 3 |
| Depreciation | 1 | 1 | 1 |
| Profit before tax | 4 | 7 | 13 |
| Tax % | 29% | 27% | 28% |
| 3 | 5 | 10 | |
| EPS in Rs | 5.59 | ||
| Dividend Payout % | 0% | 0% | 9% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 115% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 0.40 | 0.40 | 17 |
| Reserves | 12 | 17 | 45 |
| 19 | 26 | 25 | |
| 38 | 54 | 48 | |
| Total Liabilities | 69 | 98 | 135 |
| 10 | 12 | 11 | |
| CWIP | 3 | 0 | 4 |
| Investments | 0 | 0 | 0 |
| 55 | 86 | 120 | |
| Total Assets | 69 | 98 | 135 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 5 | -5 | -13 | |
| -5 | -0 | 26 | |
| 1 | 5 | -4 | |
| Net Cash Flow | 1 | -0 | 9 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 128 | 159 | 188 |
| Inventory Days | 96 | 192 | 249 |
| Days Payable | 274 | 413 | 412 |
| Cash Conversion Cycle | -50 | -62 | 25 |
| Working Capital Days | 53 | 96 | 157 |
| ROCE % | 24% | 27% |
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
11 July 2025 - Compliance certificate confirming no rematerialisation requests for June 2025 quarter.
-
Reply to Clarification- Financial results
3 July 2025 - Clarification on authorized signatories for FY25 financial results; Board approval confirmed.
-
Disclosure under SEBI Takeover Regulations
25 June 2025 - Zenith Drugs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, …
-
Clarification - Financial Results
25 June 2025 - Exchange has sought clarification from Zenith Drugs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
-
General Updates
2 June 2025 - Investor interaction video uploaded on YouTube; no price-sensitive info shared.
Business Overview:[1][2]
ZDL is a manufacturer of a range of healthcare drugs and allied products
which includes pharmaceutical formulations. It also caters to a diverse range of customers and generates revenue through various avenues, such as marketing of branded generic drugs, third-party job work manufacturing, government and institutional business, and exports through merchant dealers.